The peptide sequence of diacyl lipopeptides determines dendritic cell TLR2-mediated NK activation.
about
Adjuvant for vaccine immunotherapy of cancer--focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunityIdentification of a polyI:C-inducible membrane protein that participates in dendritic cell-mediated natural killer cell activationTLR2-dependent induction of IL-10 and Foxp3+ CD25+ CD4+ regulatory T cells prevents effective anti-tumor immunity induced by Pam2 lipopeptides in vivo.Extracellular vesicles modulate host-microbe responses by altering TLR2 activity and phagocytosis.TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy.TLR2 mediates immunity to experimental cysticercosis.Depletion of tumor-associated macrophages enhances the anti-tumor immunity induced by a Toll-like receptor agonist-conjugated peptide.Natural killer cell activation secondary to innate pattern sensing.TLR2 & Co: a critical analysis of the complex interactions between TLR2 and coreceptors.Targeting TLR2 for vaccine developmentSelf-adjuvanting lipoimmunogens for therapeutic HPV vaccine development: potential clinical impact.Cytokine responses to eye spray adjuvants for enhancing vaccine-induced immunity in chickens.The TLR-2/TLR-6 agonist macrophage-activating lipopeptide-2 augments human NK cell cytotoxicity when PGE2 production by monocytes is inhibited by a COX-2 blocker.Lipoproteins are an important bacterial component responsible for bone destruction through the induction of osteoclast differentiation and activation.Toll-like receptor 2 ligand and interferon-γ suppress anti-tumor T cell responses by enhancing the immunosuppressive activity of monocytic myeloid-derived suppressor cells.Development of a vaccine based on bacteria-mimicking tumor cells coated with novel engineered toll-like receptor 2 ligands.Type I Interferon-Independent Dendritic Cell Priming and Antitumor T Cell Activation Induced by a Mycoplasma fermentans Lipopeptide.
P2860
Q26782131-F44E93E2-1775-4F8B-A3B8-A0AACDB3E90EQ28508164-C96CFD58-7E72-4CA6-9B34-C697F5842434Q33886184-A33FF7E3-997D-40ED-85F4-002EF3437E57Q35106699-5F5BED7C-B2B2-4910-B907-A0D36CAC3940Q35510560-EA96FB4A-4F0C-4D2D-A02A-EDBE04AA12D7Q35565170-608F377B-E6A2-4AA3-BA99-31F152E9ABEEQ35886752-1528AB11-B957-40F5-B684-ADC5DF0C5B63Q37860087-D16A4841-F761-44D7-B24C-B0805959D11EQ38132733-3E55AF88-58F7-44D0-BA25-3CFAFC221125Q38233376-61962088-BFAC-4603-A573-1A2B6D974F04Q38279548-380EA06D-F5C1-45DD-B8F6-82AADE0F5417Q40728494-88A375D5-82F5-4E66-91B5-67D8772C612FQ40876421-60E0B6C7-9C4E-4ACD-AB8B-E1F0E8183ED8Q46196784-B30A7036-B3FF-406F-87BB-32BA87AA8264Q47123300-C2312250-5534-4F5B-A365-C921E41ABB36Q54943714-6D6E430F-6F4D-44FF-AC7E-EA30070964EDQ55401761-A41546FD-86D5-48A2-B841-D7BC239CB677
P2860
The peptide sequence of diacyl lipopeptides determines dendritic cell TLR2-mediated NK activation.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The peptide sequence of diacyl ...... l TLR2-mediated NK activation.
@ast
The peptide sequence of diacyl ...... l TLR2-mediated NK activation.
@en
type
label
The peptide sequence of diacyl ...... l TLR2-mediated NK activation.
@ast
The peptide sequence of diacyl ...... l TLR2-mediated NK activation.
@en
prefLabel
The peptide sequence of diacyl ...... l TLR2-mediated NK activation.
@ast
The peptide sequence of diacyl ...... l TLR2-mediated NK activation.
@en
P2093
P2860
P1433
P1476
The peptide sequence of diacyl ...... l TLR2-mediated NK activation.
@en
P2093
Koichi Fukase
Masahiro Azuma
Masahito Hashimoto
Misako Matsumoto
Ryoko Sawahata
Sayuri Yamazaki
Tsukasa Seya
Yuusuke Akao
P2860
P304
P356
10.1371/JOURNAL.PONE.0012550
P407
P577
2010-09-02T00:00:00Z